Cargando…
IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
Mechanisms of immune suppression in peripheral tissues counteract protective immunity to prevent immunopathology and are coopted by tumors for immune evasion. While lymphatic vessels facilitate T cell priming, they also exert immune suppressive effects in lymph nodes at steady-state. Therefore, we h...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279400/ https://www.ncbi.nlm.nih.gov/pubmed/30381467 http://dx.doi.org/10.1084/jem.20180654 |
_version_ | 1783378499007938560 |
---|---|
author | Lane, Ryan S. Femel, Julia Breazeale, Alec P. Loo, Christopher P. Thibault, Guillaume Kaempf, Andy Mori, Motomi Tsujikawa, Takahiro Chang, Young Hwan Lund, Amanda W. |
author_facet | Lane, Ryan S. Femel, Julia Breazeale, Alec P. Loo, Christopher P. Thibault, Guillaume Kaempf, Andy Mori, Motomi Tsujikawa, Takahiro Chang, Young Hwan Lund, Amanda W. |
author_sort | Lane, Ryan S. |
collection | PubMed |
description | Mechanisms of immune suppression in peripheral tissues counteract protective immunity to prevent immunopathology and are coopted by tumors for immune evasion. While lymphatic vessels facilitate T cell priming, they also exert immune suppressive effects in lymph nodes at steady-state. Therefore, we hypothesized that peripheral lymphatic vessels acquire suppressive mechanisms to limit local effector CD8(+) T cell accumulation in murine skin. We demonstrate that nonhematopoietic PD-L1 is largely expressed by lymphatic and blood endothelial cells and limits CD8(+) T cell accumulation in tumor microenvironments. IFNγ produced by tissue-infiltrating, antigen-specific CD8(+) T cells, which are in close proximity to tumor-associated lymphatic vessels, is sufficient to induce lymphatic vessel PD-L1 expression. Disruption of IFNγ-dependent crosstalk through lymphatic-specific loss of IFNγR boosts T cell accumulation in infected and malignant skin leading to increased viral pathology and tumor control, respectively. Consequently, we identify IFNγR as an immunological switch in lymphatic vessels that balances protective immunity and immunopathology leading to adaptive immune resistance in melanoma. |
format | Online Article Text |
id | pubmed-6279400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-62794002019-06-03 IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin Lane, Ryan S. Femel, Julia Breazeale, Alec P. Loo, Christopher P. Thibault, Guillaume Kaempf, Andy Mori, Motomi Tsujikawa, Takahiro Chang, Young Hwan Lund, Amanda W. J Exp Med Research Articles Mechanisms of immune suppression in peripheral tissues counteract protective immunity to prevent immunopathology and are coopted by tumors for immune evasion. While lymphatic vessels facilitate T cell priming, they also exert immune suppressive effects in lymph nodes at steady-state. Therefore, we hypothesized that peripheral lymphatic vessels acquire suppressive mechanisms to limit local effector CD8(+) T cell accumulation in murine skin. We demonstrate that nonhematopoietic PD-L1 is largely expressed by lymphatic and blood endothelial cells and limits CD8(+) T cell accumulation in tumor microenvironments. IFNγ produced by tissue-infiltrating, antigen-specific CD8(+) T cells, which are in close proximity to tumor-associated lymphatic vessels, is sufficient to induce lymphatic vessel PD-L1 expression. Disruption of IFNγ-dependent crosstalk through lymphatic-specific loss of IFNγR boosts T cell accumulation in infected and malignant skin leading to increased viral pathology and tumor control, respectively. Consequently, we identify IFNγR as an immunological switch in lymphatic vessels that balances protective immunity and immunopathology leading to adaptive immune resistance in melanoma. Rockefeller University Press 2018-12-03 /pmc/articles/PMC6279400/ /pubmed/30381467 http://dx.doi.org/10.1084/jem.20180654 Text en © 2018 Lane et al. http://www.rupress.org/terms/https://creativecommons.org/licenses/by-nc-sa/4.0/This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Research Articles Lane, Ryan S. Femel, Julia Breazeale, Alec P. Loo, Christopher P. Thibault, Guillaume Kaempf, Andy Mori, Motomi Tsujikawa, Takahiro Chang, Young Hwan Lund, Amanda W. IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin |
title | IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin |
title_full | IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin |
title_fullStr | IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin |
title_full_unstemmed | IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin |
title_short | IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin |
title_sort | ifnγ-activated dermal lymphatic vessels inhibit cytotoxic t cells in melanoma and inflamed skin |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279400/ https://www.ncbi.nlm.nih.gov/pubmed/30381467 http://dx.doi.org/10.1084/jem.20180654 |
work_keys_str_mv | AT laneryans ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT femeljulia ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT breazealealecp ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT loochristopherp ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT thibaultguillaume ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT kaempfandy ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT morimotomi ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT tsujikawatakahiro ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT changyounghwan ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin AT lundamandaw ifngactivateddermallymphaticvesselsinhibitcytotoxictcellsinmelanomaandinflamedskin |